chlorambucil (Leukeran) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Chlorambucil is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA. Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. There are no known drug/drug interactions with chlorambucil.   NCATS

Chemistry

  • SMILES: OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
  • InChIKey: JCKYGMPEJWAADB-UHFFFAOYSA-N
  • Mol. Mass: 304.212
  • ALogP: 3.38
  • ChEMBL Molecule:
    chlorambucil  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.9471

United States

$18.1324
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid | 4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid | 4-(p-bis(β-chloroethyl)aminophenyl)butyric acid | ambochlorin | amboclorin | chlorambucil | chloraminophen | chloraminophene | chlorbutin | chlorobutine | gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid | leukeran | n,n-di-2-chloroethyl-gamma-p-aminophenylbutyric acid | n,n-di-2-chloroethyl-γ-p-aminophenylbutyric acid | phenylbutyric acid nitrogen mustard | γ-[p-di(2-chloroethyl)aminophenyl]butyric acid

Organizations (62)

Research & Development (58)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (6)


 

Hodgkin Disease (approved 1957)

Leukemia, Lymphocytic, Chronic, B-Cell (approved 1957)

Lymphoma, Follicular (approved 1957)

Lymphoma, Non-Hodgkin (approved 1957)

Ovarian Neoplasms

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Glomerulonephritis, Membranous (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)

Lymphoma (Phase 3)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Waldenstrom Macroglobulinemia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 50
  • # of Trial Organizations: 58

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue